최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기소아청소년정신의학 = Journal of the Korean Academy of Child and Adolescent Psychiatry, v.24 no.1, 2013년, pp.13 - 20
곽영숙 (제주대학교 의학전문대학원 정신건강의학교실) , 류재성 (제주대학교병원 정신건강의학교실)
Neuroleptic malignant syndrome (NMS) is a severe iatrogenic complication of treatment with antipsychotic medication. The aim of this review is to provide the clinical characteristics and treatments of children and adolescents with NMS. Searches were conducted in Medline, Korean studies Information S...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
신경이완제 악성증후군이란 무엇인가? | 신경이완제 악성증후군(Neuroleptic malignant syndrome, NMS)은 항정신병 약물의 부작용으로써 과도한 근육 경직, 자율신경계의 불안정, 발열, 인지기능장애를 포함하는 증후군이다. NMS의 원인은 아직 명확하게 알려져 있지 않으나, 중추신경계와 말초 신경계 모두에 적용되는 과도한 도파민 차단의 결과로 추정되고 있으며, 심각한 추체외로 증상으로 발현된다. | |
신경이완제 악성증후군의 원인은 무엇으로 추정되는가? | 신경이완제 악성증후군(Neuroleptic malignant syndrome, NMS)은 항정신병 약물의 부작용으로써 과도한 근육 경직, 자율신경계의 불안정, 발열, 인지기능장애를 포함하는 증후군이다. NMS의 원인은 아직 명확하게 알려져 있지 않으나, 중추신경계와 말초 신경계 모두에 적용되는 과도한 도파민 차단의 결과로 추정되고 있으며, 심각한 추체외로 증상으로 발현된다.1)이는 항정신병 약물의 매우 드문 부작용으로, 성인에 있어 0. | |
전형 항정신병 약물 사용시 발생한 NMS의 경우 어떤 증상이 생겼다고 보고되는가? | 전형 항정신병 약물 사용시 발생한 NMS의 경우, 다수의 소아 청소년 환자가 사망하거나 영구적인 후유증을 남긴 것으로 보고되고 있다.1,37) 이에 반해 비전형 항정신병 약물의 경우 사망이 보고되지 않았고 부작용 또한 완전히 회복되었으며, 40%의 환자에서 다른 종류의 비전형 항정신병 약물을 선택하여 성공적으로 치료되었다. |
Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:187-194.
Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69:1157-1165.
Khan HM, Syed NA, Sheerani M, Khcalani B, Kamal A, Wasay M. Neuroleptic malignant syndrome: need for early diagnosis and therapy. J Ayub Med Coll Abbottabad 2006;18:17-21.
Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997;13:763-783.
Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155: 1113-1116.
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-470.
Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-882.
Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005;19:422-425.
Choi HJ, Oh SB. Neuroleptic malignant syndrome complicated with acute renal failure secondary to quetiapine: a case report. J Korean Soc Emerg Med 2010;21:278-281.
Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003;107:45-49.
Henderson T. Neuroleptic malignant syndrome in adolescents: four probable cases in the Western Cape. S Afr Med J 2011;101:405-407.
Akpaffiong MJ, Ruiz P. Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse. Psychiatr Q 1991;62:299- 309.
Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22: 389-411.
Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003;117B:57-60.
Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 2004;9:293-298.
Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington DC: American Psychiatric Association;2000.
Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol 2009;19:415-422.
Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22: 1004-1020.
Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003;2:21-35.
Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001;16:157-163.
Ghaziuddin N, Kutcher SP, Knapp P, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry 2004;43: 1521-1539.
Shoirah H, Hamoda HM. Electroconvulsive therapy in children and adolescents. Expert Rev Neurother 2011;11:127-137.
Rey JM, Walter G. Half a century of ECT use in young people. Am J Psychiatry 1997;154:595-602.
Aubas S, Biboulet P, Daures JP, du Cailar J. [Incidence and etiology of cardiac arrest occurring during the peroperative period and in the recovery room. Apropos of 102,468 anesthesia cases]. Ann Fr Anesth Reanim 1991;10:436-442.
Mansheim P. ECT in the treatment of a depressed adolescent with meningomyelocele, hydrocephalus, and seizures. J Clin Psychiatry 1983;44:385-386.
Ghaziuddin N, DeQuardo JR, Ghaziuddin M, King CA. Electroconvulsive treatment of a bipolar adolescent postcraniotomy for brain stem astrocytoma. J Child Adolesc Psychopharmacol 1999;9:63-69.
Viparelli U, Viparelli G. ECT and Grand Mal Epilepsy. Convuls Ther 1992;8:39-42.
Griesemer DA, Kellner CH, Beale MD, Smith GM. Electroconvulsive therapy for treatment of intractable seizures. Initial findings in two children. Neurology 1997;49:1389-1392.
Kutcher S, Robertson HA. Electroconvulsive therapy in treatment resistant bipolar youth. J Child Adolesc Psychopharmacol 1995;5: 167-175.
Hill MA, Courvoisie H, Dawkins K, Nofal P, Thomas B. ECT for the treatment of intractable mania in two prepubertal male children. Convuls Ther 1997;13:74-82.
Ghaziuddin N, King CA, Naylor MW, Ghaziuddin M, Chaudhary N, Giordani B, et al. Electroconvulsive treatment in adolescents with pharmacotherapy-refractory depression. J Child Adolesc Psychopharmacol 1996;6:259-271.
Bailine SH, Petrides G, Doft M, Lui G. Indications for the use of propofol in electroconvulsive therapy. J ECT 2003;19:129-132.
Schneekloth TD, Rummans TA, Logan KM. Electroconvulsive Therapy in Adolescents. Convuls Ther 1993;9:158-166.
Ghaziuddin N, Laughrin D, Giordani B. Cognitive side effects of electroconvulsive therapy in adolescents. J Child Adolesc Psychopharmacol 2000;10:269-276.
Steingard R, Khan A, Gonzalez A, Herzog DB. Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol 1992;2:183-198.
Bahn GH, Cho SC, Hong KE, Kim YS, Chung SJ. A case of Clozapine trial for a manic episode suffered by an adolescent recovering from neuroleptic malignant syndrome. Korean J Child & Adol Psychiatr 1998;9:247-252.
Dahlstrom JE, Cookman J, Jain S. Joubert syndrome: an affected female with bilateral colobomata. Pathology 2000;32:283-285.
Vurucu S, Congologlu A, Altun D, Unay B, Akin R. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. J Natl Med Assoc 2009;101:273-275.
Bellamy CJ, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma 2009;66:954-958.
Martinez HR, Cantu-Martinez L, Gonzalez HC, Flores Lde L, Villarreal HJ, Onofre-Castillo J. Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child. J Child Neurol 2006;21: 1073-1075.
Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994;10:131-140.
Lima B, Neves G, Nora M. Juvenile Parkinsonism: clinical and metabolic characteristics. J Neurol Neurosurg Psychiatry 1987;50:345-348.
Yokochi M, Narabayashi H, Iizuka R, Nagatsu T. Juvenile parkinsonism--some clinical, pharmacological, and neuropathological aspects. Adv Neurol 1984;40:407-413.
Rodnitzky RL. Drug-induced movement disorders in children and adolescents. Expert Opin Drug Saf 2005;4:191-102.
Park-Matsumoto YC, Tazawa T. [Valproate induced parkinsonism]. No To Shinkei 1998;50:81-84.
Ring HA, Trimble MR, Costa DC, Moriarty J, Verhoeff NP, Ell PJ. Striatal dopamine receptor binding in epileptic psychoses. Biol Psychiatry 1994;35:375-380.
Starr MS. The role of dopamine in epilepsy. Synapse 1996;22:159-194.
Hillis RE, Lee DA. Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatr Emerg Care 2003; 19:99-100.
Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007;30:47-51.
Erermis S, Bildik T, Tamar M, Gockay A, Karasoy H, Ercan ES. Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. Clin Toxicol (Phila) 2007;45:277-280.
Muhammed K, Raman P. Simultaneous occurrence of toxic epidermal necrolysis and neuroleptic malignant syndrome. Indian J Dermatol Venereol Leprol 2005;71:270-272.
Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004;26:1105- 1108.
Abu-Kishk I, Toledano M, Reis A, Daniel D, Berkovitch M. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 2004;42:921-925.
Hillis RE, Lee DA. Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatr Emerg Care 2003; 19:99-100.
Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004;14:481-487.
Ghaziuddin N, Alkhouri I, Champine D, Quinlan P, Fluent T, Ghaziuddin M. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment. J ECT 2002;18:95-98.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.